The webinar “CAR T-Cell Therapy: Health Care Resource Utilization + Costs in DLBCL Patients,” hosted by NCODA, is a CE-accredited session scheduled for January 27, 2026, at 2:00 PM EST.

Led by Madelyn Floysand, PharmD, the program provides a deep dive into real-world evidence from a 2025 Journal of Managed Care and Specialty Pharmacy study regarding the economic and operational impact of Chimeric Antigen Receptor T-cell therapy in Diffuse Large B-Cell Lymphoma.

The session is designed to help oncology professionals compare resource utilization – such as ICU stays and outpatient visits – between inpatient and outpatient administration models, offering practical insights to refine patient selection and interdisciplinary workflow planning.